Breaking News, Collaborations & Alliances

AcuraStem, Takeda Partner to Advance PIKFYVE Therapeutics

Takeda will receive an exclusive license to AcuraStem’s PIKFYVE program, a therapeutic target for ALS and potentially Frontotemporal Dementia.

AcuraStem, a biotechnology company pioneering treatments for neurodegenerative diseases, entered into a license agreement with Takeda to develop and commercialize AcuraStem’s PIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide (ASO) for the treatment of Amyotrophic Lateral Sclerosis (ALS). PIKFYVE is a novel therapeutic target for ALS and may also be relevant for treating additional TDP-43 proteinopathies such as Frontotemporal Dementia (FTD). AcuraStem’s t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters